Clinical Safety of Renaming Encapsulated Follicular Variant of Papillary Thyroid Carcinoma: Is NIFTP Truly Benign?

MLA

Ozgur Mete, et al. “Clinical Safety of Renaming Encapsulated Follicular Variant of Papillary Thyroid Carcinoma: Is NIFTP Truly Benign?” World Journal of Surgery, vol. 42, Aug. 2017, pp. 321–26. EBSCOhost, https://doi.org/10.1007/s00268-017-4182-5.

APA

Ozgur Mete, Pim J. Bongers, Lorne Rotstein, Wouter P. Kluijfhout, Karen Devon, Sylvia L. Asa, Raoul Verzijl, Jesse D. Pasternak, David N. Parente, & David P. Goldstein. (2017). Clinical Safety of Renaming Encapsulated Follicular Variant of Papillary Thyroid Carcinoma: Is NIFTP Truly Benign? World Journal of Surgery, 42, 321–326. https://doi.org/10.1007/s00268-017-4182-5

Chicago

Ozgur Mete, Pim J. Bongers, Lorne Rotstein, Wouter P. Kluijfhout, Karen Devon, Sylvia L. Asa, Raoul Verzijl, Jesse D. Pasternak, David N. Parente, and David P. Goldstein. 2017. “Clinical Safety of Renaming Encapsulated Follicular Variant of Papillary Thyroid Carcinoma: Is NIFTP Truly Benign?” World Journal of Surgery 42 (August): 321–26. doi:10.1007/s00268-017-4182-5.